drugset / Trial / NCT00006093
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
Phase 1/2
Completed
New Approaches to Brain Tumor Therapy Consortium
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: EMD 121974 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of EMD 121974 in treating patients who have progressive or recurrent malignant glioma.
Timeline
- Start
- 2000-09
- Primary completion
- —
- Completion
- 2006-10
Publications
- Results Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD, Grossman SA. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 2007 May 1;25(13):1651-7. doi: 10.1200/JCO.2006.06.6514.
- Results Nabors LB, Rosenfeld SS, Mikkelsen T, et al.: NABTT 9911: a phase I trial of EMD 121974 for treatment of patients with recurrent malignant gliomas. [Abstract] Neuro-Oncology 6 (4): TA-39, 379, 2004.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | cilengitide | Peptide | 120 mg/m2 | Intravenous |
| Subject | cilengitide | Peptide | 240 mg/m2 | Intravenous |
| Subject | cilengitide | Peptide | 360 mg/m2 | Intravenous |
| Subject | cilengitide | Peptide | 480 mg/m2 | Intravenous |
| Subject | cilengitide | Peptide | 600 mg/m2 | Intravenous |
| Subject | cilengitide | Peptide | 800 mg/m2 | Intravenous |
| Subject | cilengitide | Peptide | 1200 mg/m2 | Intravenous |
| Subject | cilengitide | Peptide | 1800 mg/m2 | Intravenous |
| Subject | cilengitide | Peptide | 2400 mg/m2 | Intravenous |